Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Recordati SpAMIL:REC +0.57%95 3-Year Dividend Growth Rate is 5.10% as of Jun. 2026, which is 56% below its 10-year median of 11.65. GuruFocus rates MIL:REC with a GF Score™ of 95/100 and a GF Value™ of €61.57 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 350 Drug Manufacturers companies, Recordati SpA ranks worse than 59.14% on this metric.
The historical rank and industry rank for Recordati SpA's 3-Year Dividend Growth Rate or its related term are showing as below:
MIL:REC'
s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -8 Med: 11.65 Max: 30.2
Current: 5.1
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Recordati SpA was 30.20% per year. The lowest was -8.00% per year. And the median was 11.65% per year.
MIL:REC's 3-Year Dividend Growth Rate is ranked worse than 59.14% of 350
companies
in the Drug Manufacturers industry
Industry Median: 7.7
vs MIL:REC: 5.10
During the past 12 months, Recordati SpA's average Dividends Per Share Growth Rate was 5.50% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 5.10% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 4.80% per year.
During the past 10 years, the average Dividends Per Share Growth Rate was 8.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
During the past 13 years, the highest Dividend Payout Ratio of Recordati SpA was 0.66. The lowest was 0.52. And the median was 0.57.
2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.
Recordati SpA Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
EUR 0.710000
2026-05-18
2026-05-19
2026-05-20
Cash Dividend
semi-annually
EUR:EUR 1.000000
EUR 0.630000
2025-11-24
2025-11-25
2025-11-26
Cash Dividend
semi-annually
EUR:EUR 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Recordati SpA's Dividend Yield (%) for Today is calculated as
Current Share Price is €52.65.
Recordati SpA's Dividends per Share for the trailing twelve months (TTM) ended in Today is €1.34.
During the past 13 years, the highest Dividend Yield of Recordati SpA was 3.12%. The lowest was 1.72%. And the median was 2.39%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Recordati SpA 3-Year Dividend Growth Rate Related Terms>
MIL:REC vs LLY, JNJ, ABBV: 3-Year Dividend Growth Rate Comparison
For the Drug Manufacturers - General subindustry, Recordati SpA's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recordati SpA 3-Year Dividend Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's 3-Year Dividend Growth Rate distribution charts can be found below:
* The bar in red indicates where Recordati SpA's 3-Year Dividend Growth Rate falls into.
This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Dividend Growth Rate of 5.10% mean?
Recordati SpA (MIL:REC) has a 3-Year Dividend Growth Rate of 5.10% as of Jun. 2026. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on Recordati SpA and its competitors. This is 56% below median its historical median of 11.65. According to the industry distribution chart, Recordati SpA ranks #207 out of 350 companies in the Drug Manufacturers industry, placing it in the top 59.1%.
Is Recordati SpA's 3-Year Dividend Growth Rate too high?
Recordati SpA's current 3-Year Dividend Growth Rate of 5.10% is 56% below median its 10-year median of 11.65. The Drug Manufacturers industry median 3-Year Dividend Growth Rate is 7.70. Recordati SpA's value of 5.10% is 33.8% below this industry median. Based on the distribution chart, Recordati SpA ranks #207 out of 350 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Recordati SpA has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recordati SpA's 3-Year Dividend Growth Rate compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Recordati SpA ranks #207 out of 350 companies for 3-Year Dividend Growth Rate. This places Recordati SpA in the lower half of its industry. The industry median 3-Year Dividend Growth Rate is 7.70. Recordati SpA's value of 5.10% is 33.8% below this benchmark. While the company's 10-year median is 11.65 vs. the industry median of 7.70, Recordati SpA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Dividend Growth Rate for a Drug Manufacturers company?
The median 3-Year Dividend Growth Rate among Drug Manufacturers companies is 7.70, based on 350 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Dividend Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Dividend Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Recordati SpA's current 3-Year Dividend Growth Rate of 5.10% is 33.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Dividend Growth Rate mean?
A high 3-Year Dividend Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on Recordati SpA and its competitors. For the Drug Manufacturers industry, the median 3-Year Dividend Growth Rate is 7.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Recordati SpA's current 3-Year Dividend Growth Rate is 5.10%, which is 56% below median its own 10-year median of 11.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recordati SpA stock overvalued right now?
Based on GuruFocus' analysis, Recordati SpA (MIL:REC) is currently considered Modestly Undervalued. The stock's GF Value™ is €61.57, compared to a current price of €52.65 — trading 14.5% below its estimated fair value. The current 3-Year Dividend Growth Rate is 5.10%, which is 56% below median its 10-year median of 11.65 and 33.8% below the Drug Manufacturers industry median of 7.70. Recordati SpA's overall GF Score™ is 95/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Dividend Growth Rate calculated?
3-Year Dividend Growth Rate is calculated from a company's financial statements. For Recordati SpA (MIL:REC), the current 3-Year Dividend Growth Rate is 5.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Recordati SpA (MIL:REC) Overvalued in 2026?
Based on GuruFocus' analysis, Recordati SpA stock appears to be undervalued.
The current stock price of €52.65 is trading 14.5% below its estimated GF Value™ of €61.57.
GuruFocus considers Recordati SpA to be Modestly Undervalued.
Key valuation signals for MIL:REC:
3-Year Dividend Growth Rate: 5.10% (56% below median its 10-year median of 11.65)
GF Value™: €61.57 vs. price of €52.65 (14.5% below fair value)
Industry Position: 33.8% below the Drug Manufacturers median (#207 of 350)
No single metric tells the full story. See the MIL:REC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical chemicals. The Company operates in a broad and diverse context, which includes general medicine, specialist medicine, self-medication, and rare diseases. In addition, it is also active in the field of urology, with treatments for benign prostatic hyperplasia and male functional disorders, and in psychiatry. The Company's only operating segment is the Specialty & Primary Care segment. Its geographic areas are Europe, Australasia, America, and Africa.
95GF Score
Get the complete analysis for MIL:REC
3-Year Dividend Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:REC has been successfully added to your 
